Hannah Chang is a Managing Director at Wu Capital. Dr. Chang focuses on early-stage biopharmaceutical venture capital investments out of the firm’s San Francisco office. Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), Akouos (NASDAQ: AKUS), Korro Bio, Gemini Therapeutics, and PACT Pharma.
She was previously an investment professional at 5AM Ventures where she helped found IDEAYA Biosciences (NASDAQ: IDYA) and served as a Board Observer for Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice.
Dr. Chang obtained her MD from Harvard Medical School, PhD in Biophysics from Harvard University, and BA in Chemistry from Princeton University. She trained clinically in internal medicine and ophthalmology at the Beth Israel Deaconess Medical Center and Massachusetts Eye and Ear Infirmary, respectively. She is a licensed physician in the District of Columbia.